QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation
study of ALT-801 combined with cisplatin. The purpose of this study is to evaluate the
safety, determine the Maximum-Tolerated Dose (MTD), and characterize the pharmacokinetic
profile of ALT-801 given with cisplatin in patients who are chemotherapy naïve and have
metastatic melanoma that is considered surgically incurable. The anti-tumor responses of
ALT-801 with cisplatin will also be assessed in this trial.